Hypothesis: Neural Mechanism of Psychotherapy for the Treatment of Parkinson's Disease: Cognitive Behavioral Therapy (CBT), Acceptance and Commitment Therapy (ACT), and Morita Therapy?

Overview

Journal J Neural Transm (Vienna)

Specialties Neurology
Physiology

Date 2019 Dec 7

PMID 31807951

Citations 5

Authors

Toshiharu Nagatsu

Affiliations

Soon will be listed here.

Abstract

Cognitive behavioral therapy (CBT) for depression and anxiety, established since the 1960s in the USA, and now in Europe, and all over the world has been found to be effective for treating depression in Parkinson's disease (PD). CBT is further developed to acceptance and commitment therapy (ACT) in Europe and the USA. The neural mechanism of CBT or ACT is still under investigation. In Japan, Morita therapy, a psychotherapy founded in 1919 by Masatake (Shoma) Morita, has been used for common mental problems such as anxiety and depression, but rarely for the psychological symptoms in PD. Morita Therapy is in sharp contrast to western CBT in teaching that undesired mental symptoms such as anxiety and depression are natural features of human emotion in health and disease rather than something to control or eliminate, but it is speculated to be similar to ACT in the approach to acceptance but not elimination of mental symptoms. I speculate that the neural basis might be similar in CBT, ACT, and Morita Therapy. In this commentary, a hypothesis is proposed that CBT, ACT, as well as Morita Therapy might be effective for the treatment of the psychological symptoms such as anxiety and depression in PD and in other mental and physical diseases, probably by similar neural mechanisms in the brain.

Citing Articles

Neurobiological mechanisms of dialectical behavior therapy and Morita therapy, two psychotherapies inspired by Zen.

Lin Y, Hsu C, Lin C, Kuroda R, Chiang D, Lai F J Neural Transm (Vienna). 2023; 130(8):1077-1088.

PMID: 37145166 DOI: 10.1007/s00702-023-02644-3.

A century of Morita therapy: What has and has not changed.

Nakamura M, Niimura H, Kitanishi K Asia Pac Psychiatry. 2022; 15(1):e12511.

PMID: 35403327 PMC: 10078264. DOI: 10.1111/appy.12511.

Cognitive behavioral therapy (CBT), acceptance and commitment therapy (ACT), and Morita therapy (MT); comparison of three established psychotherapies and possible common neural mechanisms of psychotherapies.

Dijkstra J, Nagatsu T J Neural Transm (Vienna). 2021; 129(5-6):805-828.

PMID: 34889976 DOI: 10.1007/s00702-021-02450-9.

Versatile Role of Prokineticins and Prokineticin Receptors in Neuroinflammation.

Lattanzi R, Miele R Biomedicines. 2021; 9(11).

PMID: 34829877 PMC: 8615546. DOI: 10.3390/biomedicines9111648.

Social Belonging as the Main Concern for Achieving Life Satisfaction When Adapting to Parkinson's Disease.

Rosengren L, Forsberg A, Brogardh C, Lexell J Int J Environ Res Public Health. 2021; 18(16).

PMID: 34444401 PMC: 8391246. DOI: 10.3390/ijerph18168653.

References

Hadinia A, Meyer A, Bruegger V, Hatz F, Nowak K, Taub E . Cognitive Behavioral Group Therapy Reduces Stress and Improves the Quality of Life in Patients with Parkinson's Disease. Front Psychol. 2017; 7:1975. PMC: 5209356. DOI: 10.3389/fpsyg.2016.01975. View

Bluett E, Homan K, Morrison K, Levin M, Twohig M . Acceptance and commitment therapy for anxiety and OCD spectrum disorders: an empirical review. J Anxiety Disord. 2014; 28(6):612-24. DOI: 10.1016/j.janxdis.2014.06.008. View

Taylor D, Meader N, Bird V, Pilling S, Creed F, Goldberg D . Pharmacological interventions for people with depression and chronic physical health problems: systematic review and meta-analyses of safety and efficacy. Br J Psychiatry. 2011; 198(3):179-88. DOI: 10.1192/bjp.bp.110.077610. View

Kawanishi H, Sekiguchi A, Funaba M, Fujii Y, Yoshiuchi K, Kikuchi H . Cognitive behavioral therapy with interoceptive exposure and complementary video materials for irritable bowel syndrome (IBS): protocol for a multicenter randomized controlled trial in Japan. Biopsychosoc Med. 2019; 13:14. PMC: 6551860. DOI: 10.1186/s13030-019-0155-2. View

Lackner J, Jaccard J, Keefer L, Brenner D, Firth R, Gudleski G . Improvement in Gastrointestinal Symptoms After Cognitive Behavior Therapy for Refractory Irritable Bowel Syndrome. Gastroenterology. 2018; 155(1):47-57. PMC: 6035059. DOI: 10.1053/j.gastro.2018.03.063. View

Ost L . The efficacy of Acceptance and Commitment Therapy: an updated systematic review and meta-analysis. Behav Res Ther. 2014; 61:105-21. DOI: 10.1016/j.brat.2014.07.018. View

McLean G, Lawrence M, Simpson R, Mercer S . Mindfulness-based stress reduction in Parkinson's disease: a systematic review. BMC Neurol. 2017; 17(1):92. PMC: 5433018. DOI: 10.1186/s12883-017-0876-4. View

Santangelo G, Garramone F, Baiano C, DIorio A, Piscopo F, Raimo S . Personality and Parkinson's disease: A meta-analysis. Parkinsonism Relat Disord. 2018; 49:67-74. DOI: 10.1016/j.parkreldis.2018.01.013. View

Schrag A, Taddei R . Depression and Anxiety in Parkinson's Disease. Int Rev Neurobiol. 2017; 133:623-655. DOI: 10.1016/bs.irn.2017.05.024. View

10.

Kwok J, Kwan J, Auyeung M, Mok V, Lau C, Choi K . Effects of Mindfulness Yoga vs Stretching and Resistance Training Exercises on Anxiety and Depression for People With Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol. 2019; 76(7):755-763. PMC: 6583059. DOI: 10.1001/jamaneurol.2019.0534. View

11.

Beck A, Ward C, Mendelson M, Mock J, ERBAUGH J . An inventory for measuring depression. Arch Gen Psychiatry. 1961; 4:561-71. DOI: 10.1001/archpsyc.1961.01710120031004. View

12.

Santangelo G, Piscopo F, Barone P, Vitale C . Personality in Parkinson's disease: Clinical, behavioural and cognitive correlates. J Neurol Sci. 2017; 374:17-25. DOI: 10.1016/j.jns.2017.01.013. View

13.

Nagatsu T, Levitt M, UDENFRIEND S . TYROSINE HYDROXYLASE. THE INITIAL STEP IN NOREPINEPHRINE BIOSYNTHESIS. J Biol Chem. 1964; 239:2910-7. View

14.

Nagatsu T, Nakashima A, Ichinose H, Kobayashi K . Human tyrosine hydroxylase in Parkinson's disease and in related disorders. J Neural Transm (Vienna). 2018; 126(4):397-409. DOI: 10.1007/s00702-018-1903-3. View

15.

Kaczkurkin A, Foa E . Cognitive-behavioral therapy for anxiety disorders: an update on the empirical evidence. Dialogues Clin Neurosci. 2015; 17(3):337-46. PMC: 4610618. View

16.

Graham C, Gouick J, Krahe C, Gillanders D . A systematic review of the use of Acceptance and Commitment Therapy (ACT) in chronic disease and long-term conditions. Clin Psychol Rev. 2016; 46:46-58. DOI: 10.1016/j.cpr.2016.04.009. View

17.

Sugg H, Richards D, Frost J . Morita Therapy for depression (Morita Trial): a pilot randomised controlled trial. BMJ Open. 2018; 8(8):e021605. PMC: 6089263. DOI: 10.1136/bmjopen-2018-021605. View

18.

Kitanishi K, Mori A . Morita therapy: 1919 to 1995. Psychiatry Clin Neurosci. 1995; 49(5-6):245-54. DOI: 10.1111/j.1440-1819.1995.tb01896.x. View

19.

Shinmei I, Kobayashi K, Oe Y, Takagishi Y, Kanie A, Ito M . Cognitive behavioral therapy for depression in Japanese Parkinson's disease patients: a pilot study. Neuropsychiatr Dis Treat. 2016; 12:1319-31. PMC: 4908947. DOI: 10.2147/NDT.S104777. View

20.

Dissanayaka N, Pye D, Mitchell L, Byrne G, OSullivan J, Marsh R . Cognitive Behavior Therapy for Anxiety in Parkinson's Disease: Outcomes for Patients and Caregivers. Clin Gerontol. 2017; 40(3):159-171. DOI: 10.1080/07317115.2016.1240131. View